Zhiwen Cheng

Zhiwen Cheng

Auto-generated profile, based on publicly available information

Zhiwen Cheng

National Clinical Research Center for Child Health, National Children’s Regional Medical Center, Hangzhou, China

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 January 2025 in Kidney Research and Clinical Practice
Verified
Journal Article
Open access
PDF file
BJBuchun Jiang
Buchun Jiang
ZCZhiwen Cheng
Zhiwen Cheng
DWDongjie Wang
Dongjie Wang
FLFei Liu
Fei Liu
JWJingjing Wang
Jingjing Wang
JMJianhua Mao
Jianhua Mao
The renoprotective effects of sodium-glucose cotransporter-2 (SGLT2) inhibitors in both diabetic and nondiabetic nephropathy are widely recognized due to results from randomized controlled trials notably the DAPA-CKD and EMPA-KIDNEY trials. Research exploring the mechanisms of renoprotection indicates that SGLT2 inhibitors exert protective effects on podocytes by enhancing autophagy and stabilizing the structure of podocytes and basement membranes. Furthermore, reductions in lipotoxicity, oxidative stress, and inflammation have been confirmed with SGLT2 inhibitor treatment. Recent clinical studies have also begun to explore the effects of SGLT2 inhibitors on nondiabetic podocytopathies, such as focal segmental glomerulosclerosis. In this review, we summarize clinical and laboratory studies that focus on the podocyte-protective effects of SGLT2 inhibitors, exploring the potential for broader applications of this novel therapeutic agent in kidney disease.